Trial Profile
Multicenter, open-label follow-up study on the safety of enteric-coated mycophenolate sodium in de novo renal transplant patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2009
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 06 Dec 2005 New trial record.